Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Curis is a drug discovery and development company focused on creating new medicines for cancer using innovative signaling pathway technologies. The company operates in a single segment: the research and development of innovative cancer therapeutics. It relies heavily on strategic collaborations (notably with Genentech) and internal development of proprietary drug candidates.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Total Revenues | $86,721 | $5,262,114 | $4,903,712 |
| Net Loss | $(4,571,451) | $(9,966,674) | $(11,256,617) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.16) | $(0.22) |
| Cash and Cash Equivalents | $5,368,050 | $5,368,050 (End of Period) | $17,881,406 (End of Period) |
| Marketable Securities | $24,560,981 | $24,560,981 (End of Period) | $24,062,577 (End of Period) |
| Total Current Assets | $30,447,070 | $30,447,070 | $42,039,096 |
| Total Liabilities | $2,752,399 | $2,752,399 | $6,972,122 |
| Accumulated Deficit | $(705,814,412) | $(705,814,412) | $(695,847,738) |
Liquidity: As of September 30, 2008, the company held approximately $29.9 million in cash, cash equivalents, and marketable securities. Management anticipates these resources will fund operations into the first half of 2010.
Material Changes vs. Prior Period
- Revenue Composition: Total revenues for the nine months ended September 30, 2008, increased 7% to $5.26 million compared to $4.90 million in the prior year. This increase was driven by a $3.0 million milestone payment from Genentech (Hedgehog pathway inhibitor) and $1.75 million in license revenue from the sale of BMP assets to Stryker Corporation. Conversely, research and development contract revenues decreased significantly (85%) as funding from prior collaborations (Wyeth, Procter & Gamble) concluded.
- Operating Expenses: Research and development expenses remained relatively flat (up 1% to $9.68 million) due to increased spending on internal programs (CUDC-101 and CUDC-305) offset by reduced costs for collaborator-funded programs. General and administrative expenses decreased 15% to $6.40 million, primarily due to lower stock-based compensation and personnel costs.
- Cash Flow: Net cash used in operating activities increased to $11.19 million for the nine months ended September 30, 2008, compared to $9.18 million in the prior year, largely due to the net loss and decreases in deferred revenue and accounts payable.
- Debt: The company repaid its remaining short-term debt of approximately $404,000 in April 2008. As of September 30, 2008, there was no current debt.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Capital Runway: Management expects existing capital resources to maintain operations into the first half of 2010. Future funding will depend on collaborations, equity/debt financings, or milestone payments.
- Cost Reductions: In October 2008, the company implemented spending reductions in general and administrative and preclinical research areas. However, R&D expenses are expected to increase in the remainder of 2008 due to clinical development of CUDC-101 and IND-enabling studies for CUDC-305.
- Executive Compensation: On October 24, 2008, executive officers agreed to base salary reductions in exchange for equity grants (stock options and restricted stock).
Key Risks and Contingencies:
- Collaboration Dependence: The company relies heavily on Genentech for the development of GDC-0449. Delays or failures in Genentech's clinical trials would materially impact Curis's prospects.
- Need for Financing: The company has never been profitable and has an accumulated deficit of over $705 million. It will require substantial additional capital to continue operations beyond mid-2010.
- Development Risks: All drug candidates are in early stages. There is no assurance that CUDC-101 or CUDC-305 will successfully complete clinical trials or receive regulatory approval.
- Stock Price Volatility: The company faces risks related to maintaining NASDAQ listing requirements (minimum bid price of $1.00) and potential dilution from future equity financings.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that current cash reserves ($29.9M) will sustain operations only until the first half of 2010.
- Genentech Milestones: Monitor the progress of Genentech's Phase II trials for GDC-0449 in colorectal cancer, ovarian cancer, and basal cell carcinoma, as future revenue is contingent on these milestones.
- Internal Pipeline Progress: Track the enrollment and safety data of the Phase I trial for CUDC-101 and the IND-enabling studies for CUDC-305.
- Collaboration Agreements: Assess the likelihood of securing new corporate collaborators for CUDC-101 and CUDC-305, as the company lacks the resources to fully fund late-stage development independently.
- Stock Price Compliance: Monitor the trading price of common stock to ensure compliance with NASDAQ Global Market listing requirements (minimum $1.00 bid price).